Preoperative portal vein or portal and hepatic vein embolization: DRAGON collaborative group analysis

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Sökning: onr:"swepub:oai:DiVA.org:liu-178425" > Preoperative portal...

1 av 1
Föregående post
Nästa post
Till träfflistan

LIBRIS Formathandbok (Information om MARC21)

Fältnamn	Indikatorer	Metadata
000		05096naa a2200637 4500
001		oai:DiVA.org:liu-178425
003		SwePub
008		210826s2021 \| \|\|\|\|\|\|\|\|\|\|\|000 \|\|eng\|
024	7	a https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-1784252 URI
024	7	a https://doi.org/10.1093/bjs/znaa1492 DOI
040		a (SwePub)liu
041		a engb eng
042		9 SwePub
072	7	a ref2 swepub-contenttype
072	7	a art2 swepub-publicationtype
100	1	a Heil, J.u Univ Zurich, Switzerland; Goethe Univ Frankfurt, Germany4 aut
245	1 0	a Preoperative portal vein or portal and hepatic vein embolization: DRAGON collaborative group analysis
264		c 2021-03-01
264	1	b OXFORD UNIV PRESS,c 2021
338		a print2 rdacarrier
520		a Y Background: The extent of liver resection for tumours is limited by the expected functional reserve of the future liver remnant (FRL), so hypertrophy may be induced by portal vein embolization (PVE), taking 6 weeks or longer for growth. This study assessed the hypothesis that simultaneous embolization of portal and hepatic veins (PVE/HVE) accelerates hypertrophy and improves resectability. Methods: All centres of the international DRAGON trials study collaborative were asked to provide data on patients who had PVE/HVE or PVE on 2016-2019 (more than 5 PVE/HVE procedures was a requirement). Liver volumetry was performed using OsiriX MD software. Multivariable analysis was performed for the endpoints of resectability rate, FLR hypertrophy and major complications using receiver operating characteristic (ROC) statistics, regression, and Kaplan-Meier analysis. Results: In total, 39 patients had undergone PVE/HVE and 160 had PVE alone. The PVE/HVE group had better hypertrophy than the PVE group (59 versus 48 per cent respectively; P=0.020) and resectability (90 versus 68 per cent; P=0.007). Major complications (26 versus 34 per cent; P=0.550) and 90-day mortality (3 versus 16 per cent respectively, P = 0.065) were comparable. Multivariable analysis confirmed that these effects were independent of confounders. Conclusion: PVE/HVE achieved better FLR hypertrophy and resectability than PVE in this collaborative experience.
650	7	a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Kirurgi0 (SwePub)302122 hsv//swe
650	7	a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Surgery0 (SwePub)302122 hsv//eng
700	1	a Korenblik, R.u Maastricht Univ, Netherlands; Maastricht Univ, Netherlands4 aut
700	1	a Heid, F.u Univ Zurich, Switzerland; Cantonal Hosp Winterthur, Switzerland4 aut
700	1	a Bechstein, W. O.u Goethe Univ Frankfurt, Germany4 aut
700	1	a Bemelmans, M.u Maastricht Univ, Netherlands4 aut
700	1	a Binkert, C.u Cantonal Hosp Winterthur, Switzerland4 aut
700	1	a Björnsson, Bergthoru Linköpings universitet,Avdelningen för kirurgi, ortopedi och onkologi,Medicinska fakulteten,Region Östergötland, Kirurgiska kliniken US4 aut0 (Swepub:liu)berbj34
700	1	a Breitenstein, S.u Cantonal Hosp Winterthur, Switzerland4 aut
700	1	a Detry, O.u Univ Liege, Belgium4 aut
700	1	a Dili, A.u Ctr Hosp Univ Dinant Godinne St Elisabeth UCL Nam, Belgium4 aut
700	1	a Dondelinger, R. F.u Univ Hosp Liege, Belgium4 aut
700	1	a Gerard, L.u Univ Hosp Liege, Belgium4 aut
700	1	a Gimenez-Maurel, T.u Miguel Univ Hosp, Spain; Univ Zaragoza, Spain4 aut
700	1	a Guiu, B.u St Eloi Univ Hosp, France4 aut
700	1	a Heise, D.u Univ Hosp Aachen, Germany4 aut
700	1	a Hertl, M.u Rush Univ, IL 60612 USA4 aut
700	1	a Kalil, J. A.u Rush Univ, IL 60612 USA4 aut
700	1	a Klein, J. J.u Rush Univ, IL 60612 USA4 aut
700	1	a Lakoma, A.u McGill Univ, Canada4 aut
700	1	a Neumann, U. P.u Univ Hosp Aachen, Germany4 aut
700	1	a Olij, B.u Maastricht Univ, Netherlands4 aut
700	1	a Pappas, S. G.u Rush Univ, IL 60612 USA4 aut
700	1	a Sandström, Peru Linköpings universitet,Avdelningen för kirurgi, ortopedi och onkologi,Medicinska fakulteten,Region Östergötland, Kirurgiska kliniken US4 aut0 (Swepub:liu)persa07
700	1	a Schnitzbauer, A.u Goethe Univ Frankfurt, Germany4 aut
700	1	a Serrablo, A.u Miguel Univ Hosp, Spain; Univ Zaragoza, Spain4 aut
700	1	a Tasse, J.u Rush Univ, IL 60612 USA4 aut
700	1	a Van der Leij, C.u Maastricht Univ, Netherlands4 aut
700	1	a Metrakos, P.u McGill Univ, Canada4 aut
700	1	a Van Dam, R.u Maastricht Univ, Netherlands; Maastricht Univ, Netherlands; Univ Hosp Aachen, Germany4 aut
700	1	a Schadde, E.u Univ Zurich, Switzerland; Cantonal Hosp Winterthur, Switzerland; Rush Univ, IL 60612 USA4 aut
710	2	a Univ Zurich, Switzerland; Goethe Univ Frankfurt, Germanyb Maastricht Univ, Netherlands; Maastricht Univ, Netherlands4 org
773	0	t British Journal of Surgeryd : OXFORD UNIV PRESSg 108:7, s. 834-842q 108:7<834-842x 0007-1323x 1365-2168
856	4 8	u https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-178425
856	4 8	u https://doi.org/10.1093/bjs/znaa149

Hitta via bibliotek

British Journal of Surgery (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

1 av 1
Föregående post
Nästa post
Till träfflistan

Hitta mer i SwePub

Om ämnet

MEDICIN OCH HÄLSOVETENSKAP: MEDICIN OCH HÄLS ...; och Klinisk medicin; och Kirurgi

Artiklar i publikationen: British Journal ...

Av lärosätet: Linköpings universitet

Sök utanför SwePub

Sök vidare i:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se